Stock listing
GPW:RVU Ryvu Therapeutics SA Akcje
Home listing (GPW) of Ryvu Therapeutics SA
Follow Ryvu Therapeutics SA into a list and get an email when it puts out news.
Share price · GPW:RVU
16.18 PLN -0.72 (-4.3%)
Close on Nov 20, 2026
- Day range
- 16.02 – 16.86 PLNNov 20, 2026
- Volume
- 19,982 sharesNov 20, 2026
- Market cap
- 374.1M PLNAt the close on Nov 20, 2026 · price × 23.12M shares outstanding
- 52-week range
- 13.64 – 31.90 PLNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 409,433 PLNMedian day 17,560 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| GPW:RVU · Home | 16.18 PLN | -0.72 (-4.3%) | 19,982 | 16.62 | 16.86 | 16.02 | 16.90 | Close on Nov 20, 2026 |
| Frankfurt:9Y4 | €3.62 EUR | -0.025 (-0.7%) | — | €3.62 | €3.62 | €3.62 | €3.645 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · GPW:RVU · PLN, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 16.18 | -0.72 | -4.3% | 16.62 | 16.86 | 16.02 | 19,982 | |
| 16.90 | +0.02 | +0.1% | 16.86 | 17.16 | 16.50 | 13,144 | |
| 16.88 | -0.72 | -4.1% | 17.50 | 17.50 | 16.50 | 16,747 | |
| 17.60 | -0.40 | -2.2% | 17.46 | 17.80 | 17.20 | 12,652 | |
| 18.00 | +0.28 | +1.6% | 17.72 | 18.14 | 17.62 | 15,674 | |
| 17.72 | +0.52 | +3.0% | 17.24 | 18.10 | 16.92 | 26,277 | |
| 17.20 | +0.88 | +5.4% | 16.32 | 17.22 | 16.22 | 16,298 | |
| 16.32 | -0.12 | -0.7% | 16.44 | 16.60 | 16.24 | 11,100 | |
| 16.44 | -0.38 | -2.3% | 16.68 | 17.02 | 16.40 | 12,810 | |
| 16.82 | +0.26 | +1.6% | 16.68 | 17.40 | 16.42 | 15,479 | |
| 16.56 | +0.46 | +2.9% | 16.14 | 16.92 | 16.00 | 13,705 | |
| 16.10 | -0.12 | -0.7% | 16.50 | 16.50 | 16.02 | 19,060 | |
| 16.22 | -0.76 | -4.5% | 16.70 | 16.94 | 15.92 | 30,708 | |
| 16.98 | -0.82 | -4.6% | 17.80 | 17.86 | 16.52 | 75,603 | |
| 17.80 | -0.42 | -2.3% | 18.02 | 18.44 | 17.52 | 38,748 | |
| 18.22 | -0.38 | -2.0% | 18.78 | 18.78 | 18.04 | 20,710 | |
| 18.60 | -0.06 | -0.3% | 18.78 | 18.86 | 18.00 | 25,417 | |
| 18.66 | +0.88 | +4.9% | 17.96 | 18.90 | 17.78 | 125,376 | |
| 17.78 | +0.08 | +0.5% | 17.70 | 17.98 | 17.40 | 37,101 | |
| 17.70 | +0.32 | +1.8% | 17.52 | 18.02 | 17.34 | 29,651 | |
| 17.38 | +0.32 | +1.9% | 17.06 | 17.88 | 17.06 | 12,759 | |
| 17.06 | -0.74 | -4.2% | 17.90 | 17.90 | 16.80 | 17,474 | |
| 17.80 | -0.24 | -1.3% | 18.08 | 18.08 | 16.28 | 27,023 | |
| 18.04 | +0.60 | +3.4% | 17.30 | 18.06 | 17.30 | 40,385 | |
| 17.44 | +0.54 | +3.2% | 17.80 | 17.90 | 17.22 | 28,966 | |
| 16.90 | -0.30 | -1.7% | 17.10 | 17.18 | 16.60 | 17,891 | |
| 17.20 | +0.06 | +0.4% | 17.38 | 17.50 | 16.98 | 27,088 | |
| 17.14 | +0.64 | +3.9% | 16.62 | 17.18 | 16.52 | 17,560 | |
| 16.50 | +0.22 | +1.4% | 16.30 | 16.60 | 16.20 | 14,498 | |
| 16.28 | +0.22 | +1.4% | 16.14 | 16.36 | 16.00 | 11,999 | |
| 16.06 | +0.08 | +0.5% | 16.10 | 16.30 | 15.80 | 19,528 | |
| 15.98 | +0.18 | +1.1% | 15.80 | 16.00 | 15.66 | 5,930 | |
| 15.80 | +0.30 | +1.9% | 16.00 | 16.00 | 15.44 | 5,928 | |
| 15.50 | -0.12 | -0.8% | 15.58 | 15.66 | 15.48 | 9,673 | |
| 15.62 | -0.02 | -0.1% | 15.90 | 16.00 | 15.54 | 7,133 | |
| 15.64 | -0.26 | -1.6% | 16.00 | 16.00 | 15.62 | 7,803 | |
| 15.90 | -0.18 | -1.1% | 16.08 | 16.08 | 15.62 | 8,372 | |
| 16.08 | +0.14 | +0.9% | 16.02 | 16.14 | 15.86 | 9,037 | |
| 15.94 | +0.02 | +0.1% | 15.92 | 16.10 | 15.74 | 8,764 | |
| 15.92 | +0.08 | +0.5% | 15.84 | 15.98 | 15.70 | 8,645 | |
| 15.84 | -0.16 | -1.0% | 16.10 | 16.20 | 15.82 | 13,162 | |
| 16.00 | +0.10 | +0.6% | 16.00 | 16.18 | 15.86 | 15,979 | |
| 15.90 | +0.10 | +0.6% | 16.20 | 16.34 | 15.82 | 34,914 | |
| 15.80 | -0.52 | -3.2% | 16.32 | 16.98 | 15.60 | 55,241 | |
| 16.32 | -0.38 | -2.3% | 16.62 | 16.76 | 16.02 | 28,245 | |
| 16.70 | 0.00 | 0.0% | 16.76 | 16.76 | 16.50 | 7,545 | |
| 16.70 | -0.28 | -1.6% | 16.94 | 16.94 | 16.60 | 29,588 | |
| 16.98 | -0.06 | -0.4% | 17.06 | 17.18 | 16.94 | 4,710 | |
| 17.04 | -0.32 | -1.8% | 17.30 | 17.38 | 16.98 | 18,452 | |
| 17.36 | -0.24 | -1.4% | 17.52 | 17.60 | 17.02 | 16,745 | |
| 17.60 | -0.30 | -1.7% | 17.98 | 18.42 | 17.60 | 35,690 | |
| 17.90 | +0.58 | +3.3% | 17.50 | 17.92 | 17.36 | 25,003 | |
| 17.32 | +0.24 | +1.4% | 17.08 | 17.32 | 16.72 | 13,331 | |
| 17.08 | +0.10 | +0.6% | 16.98 | 17.10 | 16.70 | 11,524 | |
| 16.98 | -0.38 | -2.2% | 17.42 | 17.60 | 16.72 | 17,307 | |
| 17.36 | -0.02 | -0.1% | 17.10 | 17.36 | 16.52 | 48,909 | |
| 17.38 | -0.30 | -1.7% | 17.68 | 17.68 | 17.10 | 28,925 | |
| 17.68 | -0.70 | -3.8% | 18.30 | 18.30 | 17.58 | 21,035 | |
| 18.38 | 0.00 | 0.0% | 18.30 | 18.48 | 18.08 | 8,043 | |
| 18.38 | -0.12 | -0.6% | 18.26 | 18.46 | 18.02 | 12,179 | |
| 18.50 | +0.10 | +0.5% | 18.40 | 18.54 | 18.00 | 37,983 | |
| 18.40 | -0.40 | -2.1% | 18.90 | 18.90 | 18.10 | 27,917 | |
| 18.80 | +0.70 | +3.9% | 18.10 | 18.88 | 18.10 | 36,665 | |
| 18.10 | -0.32 | -1.7% | 18.60 | 18.60 | 17.32 | 64,029 | |
| 18.42 | -0.14 | -0.8% | 18.92 | 19.38 | 18.30 | 38,418 |
- Ticker
- GPW:RVU
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- GPW
- Currency
- PLN
What changed lately
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 41 slides
Latest news
Ryvu Therapeutics SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in all · newest May 16, 2024 · oldest 2022
- Decks
- 21 decks · latest November 2026
Where Ryvu Therapeutics SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| GPW:RVU · Home listing · This page | GPW | Poland | PLN |
| Lang & Schwarz:A1JUH2 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A1JUH2 | LS Exchange | Germany | EUR |
| LSE:0RKT | LSE | United Kingdom | PLN |
| Frankfurt:9Y4 | Frankfurt | Germany | EUR |
| Stuttgart:9Y4 | Stuttgart | Germany | EUR |
| Dusseldorf:9Y4 | Dusseldorf | Germany | EUR |
Valuation
EV/sales 6.0× against a median of 0.6×: the highest of 5 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 374.3M PLN
- P/E
- Loss
- EV/sales
- 6.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 13.2×
- Gross margin
- −49.0%
- Operating margin
- −134.7%
- Net margin
- −109.9%
- Debt to equity
- 2.6×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ryvu Therapeutics SA · GPW:RVU | US$92.14M | US$92.19M | n/a | 6.0× | n/a | 13.2× | −109.9% | 2.6× | n/a |
| Allergy Therapeutics plc · LSE:AGY | US$95.27M | US$117.1M | n/a | 1.6× | n/a | 17.1× | −72.9% | 6.3× | n/a |
| Voyager Therapeutics, Inc. · NASDAQ:VYGR | US$95.21M | −US$11.60M | n/a | −0.5× | n/a | 0.7× | −416.3% | 0.0× | 1.45 |
| Outlook Therapeutics, Inc. · NASDAQ:OTLK | US$94.94M | US$83.70M | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Molecular Partners AG · SIX:MOLN | US$93.53M | −US$4.92M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Sunhawk Vision Biotech, Inc. · TPEX:7759 | US$93.04M | US$82.43M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| HLB Life Science Co.,Ltd. · KRX:067630 | US$92.22M | US$125.9M | n/a | 3.1× | n/a | 0.4× | −60.9% | 0.2× | n/a |
| Brii Biosciences Limited · HKEX:2137 | US$91.58M | −US$173.2M | n/a | −63.7× | n/a | 0.3× | n/a | 0.0× | n/a |
| TWi Biotechnology, Inc · TPEX:6610 | US$91.56M | US$88.17M | n/a | n/a | n/a | 6.3× | n/a | 0.0× | n/a |
| NeOnc Technologies Holdings, Inc. · NASDAQ:NTHI | US$90.88M | US$85.02M | n/a | n/a | n/a | n/a | n/a | n/a | 1.44 |
| Zura Bio Limited · NASDAQ:ZURA | US$89.63M | −US$98.02M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.52 |
| Median of the others | US$92.63M | US$83.06M | 0.6× | 0.8× | −72.9% | 0.0× | 1.44 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.90 PLN · Analysts' mean
- EPS, year to Dec 2026
- -1.88 · 2 analysts
- Revenue, year to Dec 2026
- 92M · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Pawel Przewiezlikowski | Chief Executive Officer |
| Kamil Sitarz | Chief Operating Officer |
| Hendrik Nogai | Chief Medical Officer |
| Justyna Żółtek | Chief People Officer |
| Krzysztof Brzozka | Chief Scientific Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | Mar 13, 2025 · Before open | −2.2% |
| Q3 2024 | Nov 7, 2024 | +8.3% |
| Q1 2024 | May 15, 2024 · Before open | +3.1% |
| Q4 2023 | Mar 13, 2024 · Before open | −2.6% |
| Q3 2023 | Nov 29, 2023 · After close | −1.5% |
| Q2 2023 | Sep 13, 2023 · Before open | +0.7% |
| Q1 2023 | May 16, 2023 · After close | −4.1% |
| Q4 2022 | Mar 24, 2023 · After close | −3.7% |
| Q3 2022 | Nov 23, 2022 · After close | +0.2% |
| Q2 2022 | Sep 28, 2022 · After close | −0.6% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2022 | May 18, 2022 · After close | −4.4% |
| Q4 2021 | Mar 15, 2022 · Before open | −0.4% |
| Q3 2021 | Nov 10, 2021 · After close | −0.6% |
| Quarter to Jun 30, 2021 | Sep 8, 2021 · After close | −1.7% |
| Quarter to Mar 31, 2021 | May 12, 2021 · Before open | +2.0% |
| Quarter to Dec 31, 2020 | Mar 16, 2021 · After close | −0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 41 slides | November 2026 |
| Investor Presentation (September 2026) | Investor deck | 40 slides | September 2026 |
| Investor Presentation (June 2025) | Investor deck | 49 slides | June 2025 |
| Investor Presentation (May 2025) | Investor deck | 50 slides | May 7, 2025 |
| Investor Presentation (March 2025) | Investor deck | 48 slides | March 2025 |
| Investor Presentation (July 2024) | Investor deck | 48 slides | July 2024 |
| Investor Presentation (June 2024) | Investor deck | 48 slides | June 2024 |
| Investor Presentation (April 2024) | Investor deck | 46 slides | April 2024 |
| Investor Presentation (March 2024) | Investor deck | 46 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 46 slides | January 2024 |
All 21 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2023) | Investor deck | 44 slides | November 2023 |
| Investor Presentation (October 2023) | Investor deck | 44 slides | October 2023 |
| Investor Presentation (September 2023) | Investor deck | 41 slides | Sep 19, 2023 |
| Investor Presentation (August 2023) | Investor deck | 42 slides | August 2023 |
| EHA 2023 | Conference | 30 slides | Jun 9, 2023 |
| Investor Presentation (May 2023) | Investor deck | 44 slides | May 2023 |
| Investor Presentation (December 2022) | Investor deck | 46 slides | December 2022 |
| Investor Presentation (November 2022) | Investor deck | 45 slides | November 2022 |
| Investor Presentation (August 2022) | Investor deck | 43 slides | August 2022 |
| Webinar: Podstawy transferu wiedzy i technologii (December 2021) | Conference | 31 slides | Dec 1, 2021 |
| Investor Presentation (July 2020) | Investor deck | 54 slides | July 2020 |
Financials
Annual, in PLN
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.3M | 78.0M | 46.9M | 38.8M | 11.2M | 15.4M | 42.6M | 77.2M | 87.8M | 48.1M |
| Cost of revenue | 179.3M | 19.6M | 17.6M | 17.4M | 13.7M | 8.76M | 92.7M | 29.7M | 25.9M | 16.9M |
| Gross profit | -117.0M | 58.4M | 29.3M | 21.4M | -2.54M | 6.65M | -50.2M | 47.6M | 61.9M | 31.3M |
| Research and development | 26.0M | 15.0M | 13.0M | 67.6M | 53.9M | 27.1M | 17.3M | |||
| Selling, general and administrative | 5.56M | 4.33M | 5.47M | 55.8M | 22.1M | 17.9M | 10.5M | |||
| Operating income | -122.2M | -122.1M | -100.9M | -78.4M | -103.8M | -35.7M | -45.1M | -13.6M | 12.6M | -1.21M |
| Depreciation and amortization | 9.44M | 10.5M | 11.0M | 12.9M | 12.6M | 12.4M | 7.99M | 7.09M | 5.24M | 3.62M |
| EBITDA | -112.7M | -111.6M | -90.0M | -65.5M | -91.2M | -23.3M | -37.2M | -6.52M | 17.9M | 2.40M |
| Interest expense | 8.80M | 3.81M | 97.0K | 1.09M | 442.0K | 387.4K | 398.3K | 291.5K | 231.2K | 35.8K |
| Income before tax | -101.1M | -111.1M | -92.1M | -79.2M | -79.0M | -30.6M | -36.0M | 8.99M | 9.60M | -1.28M |
| Income tax | 88.0K | 297.0K | 4.59M | 115.9K | 1.07M | -30.0K | 8.09M | 2.87M | -3.97M | |
| Net income | -101.2M | -111.4M | -92.1M | -83.8M | -79.1M | -31.7M | -36.0M | -106.3K | 6.41M | 2.72M |
| Earnings per share, basic | -4.38 | -4.82 | -4.02 | -4.57 | -4.31 | -1.89 | -2.25 | -0.01 | 0.47 | 0.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 59.6M | 160.1M | 57.9M | 101.9M | 83.2M | 136.2M | 72.1M | 110.4M | 36.1M | 29.1M |
| Short-term investments | 48.1M | 65.9M | 175.7M | 528.0K | 4.99M | 25.0M | -196.0K | -196.0K | ||
| Receivables | 20.1M | 20.9M | 9.19M | 5.05M | 11.7M | 7.95M | 15.0M | 21.4M | 19.8M | 16.4M |
| Inventory | 1.33M | 1.21M | 2.12M | 1.76M | 1.96M | 1.68M | 1.59M | 1.99M | 1.59M | 1.40M |
| Current assets | 139.3M | 272.4M | 278.4M | 367.9M | 104.2M | 172.4M | 90.0M | 173.2M | 59.9M | 47.7M |
| Property, plant and equipment | 91.2M | 91.2M | 66.2M | 39.7M | 31.4M | 21.8M | ||||
| Goodwill | 280.7K | 280.7K | 280.7K | |||||||
| Total assets | 224.4M | 378.8M | 403.2M | 475.0M | 228.8M | 295.6M | 182.9M | 255.7M | 103.6M | 89.1M |
| Accounts payable | 16.2M | 31.1M | 23.1M | 12.6M | 11.7M | 6.26M | 13.4M | 16.7M | 9.37M | 6.79M |
| Current liabilities | 61.6M | 107.9M | 69.7M | 44.8M | 36.2M | 33.8M | 30.6M | 35.6M | 26.8M | 18.9M |
| Long-term debt | 70.3M | 73.3M | 0 | 0 | 742.4K | 1.55M | 2.36M | 3.17M | 3.98M | 4.79M |
| Total debt | 71.7M | 75.5M | 906.0K | 2.77M | 5.07M | 7.41M | 9.22M | 13.5M | 7.99M | 9.62M |
| Total liabilities | 153.7M | 234.9M | 143.6M | 131.6M | 59.4M | 71.9M | 63.1M | 60.8M | 39.6M | 33.4M |
| Shareholders' equity | 53.8M | 143.9M | 259.6M | 343.4M | 161.3M | 223.7M | 119.8M | 191.9M | 62.3M | 55.4M |
| Shares outstanding | 23.1M | 23.1M | 22.9M | 18.3M | 18.4M | 16.8M | 16.0M | 15.5M | 13.8M | 13.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -110.3M | -129.5M | -84.5M | 21.3M | -57.9M | -10.6M | -17.4M | -36.4M | 11.0M | -6.28M |
| Capital spending | -7.47M | -5.90M | -8.58M | -9.29M | -12.0M | -34.2M | -24.0M | -23.4M | -21.6M | -21.2M |
| Free cash flow | -117.8M | -135.4M | -88.1M | 12.0M | -69.8M | -44.8M | -41.4M | -59.9M | -10.6M | -27.5M |
| Cash from investing | 13.3M | 137.2M | -195.5M | 690.0K | 8.06M | -55.9M | -7.94M | -37.2M | -21.5M | -18.4M |
| Cash from financing | -3.05M | 94.2M | 240.8M | -2.46M | -3.17M | 130.7M | 2.59M | 147.9M | 17.6M | 25.0M |
| Share buybacks | 143.1M | -2.99M | 134.2M | 935.9K | 327.9K | |||||
| Change in cash | -100.5M | 102.1M | -44.0M | 18.7M | -53.0M | 64.1M | -22.8M | 74.2M | 7.03M | 288.1K |
Cap table
Built by 6ix from Ryvu Therapeutics SA’s releases
- Common shares
- 23,120,148
- Fully diluted
- 23,120,148
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 23,120,148 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 23,120,148 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Hendrik Nogai | Chief Medical Officer · Since at least Nov 5, 2026 |
| Justyna Żółtek | Chief People Officer · Since at least Nov 5, 2026 |
| Kamil Sitarz | Chief Operating Officer · Since at least Nov 5, 2026 |
| Krzysztof Brzozka | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Pawel Przewiezlikowski | Chief Executive Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Ryvu Therapeutics SA.